Abstract OBJECTIVE: To evaluate the cost-effectiveness of introducing the RTS,S malaria vaccine into the Expanded Programme on Immunization (EPI) in Sub-Saharan Africa (SSA), the contributions of different sources of uncertainty, and the associated expected value of perfect information (EVPI). METHODS: Vaccination was simulated in populations of 100,000 people at 10 different entomological inoculation rates (EIRs), using an existing stochastic model and a 10-year time horizon. Incremental cost-effectiveness ratios (ICERs) and EVPI were computed from weighted averages of outputs using two different assignments of the EIR distribution in 2007. Uncertainty was evaluated by resampling of epidemiological, vaccination, and health systems ...
OBJECTIVES: To evaluate the relative cost-effectiveness of introducing the RTS,S malaria vaccine in ...
The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine ...
We predict the effects of introduction of a pre-erythrocytic vaccine against Plasmodium falciparum i...
Abstract OBJECTIVE: To evaluate the cost-effectiveness of introducing the RTS,S malaria vaccine ...
OBJECTIVE: To evaluate the cost-effectiveness of introducing the RTS,S malaria vaccine into the Expa...
AbstractObjectiveTo evaluate the cost-effectiveness of introducing the RTS,S malaria vaccine into th...
We model the cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the E...
Background A wide range of possible malaria vaccines is being considered and there is a need to i...
Abstract. We model the cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine ...
Background A wide range of possible malaria vaccines is being considered and there is a need to i...
Background: RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation i...
Background: The RTS,S/AS01 E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part of...
Background: The RTS,S/AS01 E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part o...
<div><h3>Background</h3><p>The RTS,S malaria vaccine may soon be licensed. Models of impact of such ...
AbstractBackgroundRTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementat...
OBJECTIVES: To evaluate the relative cost-effectiveness of introducing the RTS,S malaria vaccine in ...
The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine ...
We predict the effects of introduction of a pre-erythrocytic vaccine against Plasmodium falciparum i...
Abstract OBJECTIVE: To evaluate the cost-effectiveness of introducing the RTS,S malaria vaccine ...
OBJECTIVE: To evaluate the cost-effectiveness of introducing the RTS,S malaria vaccine into the Expa...
AbstractObjectiveTo evaluate the cost-effectiveness of introducing the RTS,S malaria vaccine into th...
We model the cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the E...
Background A wide range of possible malaria vaccines is being considered and there is a need to i...
Abstract. We model the cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine ...
Background A wide range of possible malaria vaccines is being considered and there is a need to i...
Background: RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation i...
Background: The RTS,S/AS01 E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part of...
Background: The RTS,S/AS01 E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part o...
<div><h3>Background</h3><p>The RTS,S malaria vaccine may soon be licensed. Models of impact of such ...
AbstractBackgroundRTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementat...
OBJECTIVES: To evaluate the relative cost-effectiveness of introducing the RTS,S malaria vaccine in ...
The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine ...
We predict the effects of introduction of a pre-erythrocytic vaccine against Plasmodium falciparum i...